Valuation: AbbVie Inc.

Capitalization 363B 310B 284B 269B 496B 34,028B 507B 3,335B 1,314B 16,299B 1,361B 1,333B 57,830B P/E ratio 2026 *
23.5x
P/E ratio 2027 * 18.4x
Enterprise value 415B 354B 325B 307B 567B 38,934B 580B 3,815B 1,503B 18,649B 1,557B 1,525B 66,166B EV / Sales 2026 *
6.19x
EV / Sales 2027 * 5.56x
Free-Float
96.39%
Yield 2026 *
3.36%
Yield 2027 * 3.51%
1 day-2.20%
1 week-4.64%
Current month-7.81%
1 month-2.23%
3 months-7.24%
6 months-13.35%
Current year-12.25%
1 week 199.81
Extreme 199.81
212.35
1 month 199.81
Extreme 199.81
220.45
Current year 199.81
Extreme 199.81
237.11
1 year 174.4
Extreme 174.4
244.81
3 years 130.96
Extreme 130.9601
244.81
5 years 105.56
Extreme 105.56
244.81
10 years 55.06
Extreme 55.0623
244.81
Manager TitleAgeSince
Chief Executive Officer 55 30/06/2024
Director of Finance/CFO 59 22/06/2022
Compliance Officer - 31/12/2023
Director TitleAgeSince
Director/Board Member 65 31/12/2012
Director/Board Member 74 31/12/2012
Director/Board Member 68 31/12/2012
Change 5d. change 1-year change 3-years change Capi.($)
-2.25%-4.64%+17.83%+23.45% 363B
+2.04%-0.11%+12.65%+139.20% 808B
-0.03%-5.83%+44.09%+38.98% 545B
-2.28%+0.60%+25.20%+13.86% 325B
-0.16%-2.56%+43.58%+19.28% 305B
-0.45%-3.91%+27.53%+30.00% 284B
+0.29%-5.89%+45.01%-2.15% 278B
+0.31%-1.43%+26.40%+41.85% 186B
+0.77%+1.16%-40.89%-57.22% 172B
-0.29%-5.38%+27.38%+53.52% 165B
Average -0.27%-2.52%+22.88%+30.08% 343.13B
Weighted average by Cap. -0.01%-2.48%+24.75%+48.76%

Financials

2026 *2027 *
Net sales 67.06B 57.22B 52.49B 49.64B 91.61B 6,290B 93.64B 616B 243B 3,013B 252B 246B 10,689B 72.5B 61.86B 56.74B 53.67B 99.04B 6,800B 101B 666B 262B 3,257B 272B 266B 11,555B
Net income 15.87B 13.55B 12.42B 11.75B 21.69B 1,489B 22.17B 146B 57.47B 713B 59.54B 58.31B 2,530B 19.63B 16.75B 15.36B 14.53B 26.82B 1,841B 27.41B 180B 71.08B 882B 73.63B 72.11B 3,129B
Net Debt 52.3B 44.63B 40.93B 38.72B 71.45B 4,905B 73.03B 481B 189B 2,350B 196B 192B 8,336B 40.62B 34.66B 31.79B 30.07B 55.49B 3,810B 56.73B 373B 147B 1,825B 152B 149B 6,475B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
22/04/26 200.50 $ -2.25% 7,643,711
21/04/26 205.12 $ +0.69% 7,772,128
20/04/26 203.71 $ -2.24% 5,774,268
17/04/26 208.38 $ -0.29% 8,986,577
16/04/26 208.99 $ +0.27% 5,075,394
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
205.12USD
Average target price
249.43USD
Spread / Average Target
+21.60%

Quarterly revenue - Rate of surprise